Review
Gastroenterology & Hepatology
Xiaozhong Wang, Lai Wei
Summary: GT3 infection is associated with rapid hepatic disease progression, and early HCV clearance is crucial for improving prognosis, especially in cirrhotic patients. The characteristics and treatment outcomes of GT3 infection in China differ significantly from those in Western countries, with GT3b infection posing a challenge to cure. Further research and tailored treatment strategies are needed to address this clinical gap.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Mohammad Said Ramadan, Filomena Boccia, Simona Maria Moretto, Fabrizio De Gregorio, Massimo Gagliardi, Domenico Iossa, Emanuele Durante-Mangoni, Rosa Zampino
Summary: The study found a positive correlation between FIB-4 and ASCVD scores at any time point after treatment. The results suggest that FIB-4 scores may have utility in cardiovascular risk assessment.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Aminata Sy, Leanne McCabe, Emma Hudson, Azim M. Ansari, Vincent Pedergnana, Shang-Kuan Lin, S. Santana, Marzia Fiorino, Aftab Ala, Ben Stone, M. Smith, Mark Nelson, Stephen T. Barclay, Stuart McPherson, Stephen D. Ryder, Jane Collier, Eleanor Barnes, Ann Sarah Walker, Sarah L. Pett, Graham Cooke
Summary: The CC genotype of the IFNL4 gene is associated with increased Hepatitis C cure rates. The Genedrive (R) IFNL4 is a CE marked Point of Care molecular diagnostic test for rapid detection of IFNL4 genotype status. Comparing buccal swab PoC testing with genetic sequencing, the buccal swab test showed better accuracy in identifying non-CC genotypes than CC genotypes.
Article
Virology
Anshuman Elhence, Achintya Singh, Abhinav Anand, Ramesh Kumar, Anzar Ashraf, Sonu Kumar, Dibyabhaba Pradhan, Piyush Pathak, Manas Vaishnav, Mahendra Singh Rajput, Vikas Banyal, Baibaswata Nayak, Shalimar
Summary: This study analyzed the outcomes of re-treatment among chronic hepatitis C patients with previous DAA treatment failure. The results showed that re-treatment with pan-genotypic DAAs achieved high SVR12 rates, regardless of genotype or the presence of resistance-associated substitutions (RAS).
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Pharmacology & Pharmacy
Yu Fang, Chung-Yu Chen, Hsien-Chung Yu, Pei-Chin Lin
Summary: This retrospective cohort study used Taiwan's National Health Insurance Research Database to evaluate the difference in incidence of neuropsychological disorders (NPDs) between chronic hepatitis C patients receiving interferon therapy and direct-acting antivirals (DAAs) therapy. The study found that patients receiving DAA therapy had a lower risk of NPDs compared to those receiving interferon therapy during the 6-month period after treatment completion.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Immunology
Sabin Nsanzimana, Michael J. Penkunas, Carol Y. Liu, Dieudonne Sebuhoro, Alida Ngwije, Eric Remera, Justine Umutesi, Cyprien Ntirenganya, Soline D. Mugeni, Janvier Serumondo
Summary: This study examined the effectiveness of DAAs in patients treated through the Rwandan national health system and identified factors associated with treatment outcomes. Results showed that DAAs were effective in achieving SVR12 in a majority of patients, but higher pretreatment HCV RNA levels were associated with virological failure. Additionally, patients in Western Province were more likely to experience nonvirological failure due to longer travel time for testing and treatment.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Health Care Sciences & Services
Joo Hyun Oh, Dong Ah Park, Min Jung Ko, Jeong-Ju Yoo, Sun Young Yim, Ji-Hyun Ahn, Dae Won Jun, Sang Bong Ahn
Summary: The risk of HBV reactivation is higher in patients with HBV/HCV co-infection receiving DAA therapy, but can be reduced with prophylactic anti-HBV treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Immunology
Eiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Jun Hayashi
Summary: This study reveals that older patients aged 75-84 years remain at high risk for developing HCC even after the elimination of HCV and improvement of the FIB-4 index to <3.25.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Gastroenterology & Hepatology
Andrea Lombardi, Marta Colaneri, Kesav Aditya Vijayagopal, Margherita Sambo, Patrizia Legnazzi, Paolo Sacchi, Valentina Zuccaro, Laura Maiocchi, Renato Maserati, Roberto Gulminetti, Layla Pagnucco, Stefano Novati, Domenico Zanaboni, Giuseppe Michelone, Serena Ludovisi, Mario U. Mondelli, Raffaele Bruno
Summary: The study found that the population of CHC patients receiving DAAs is getting older and with more comorbidities, but this did not affect the sustained virological response rates.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Immunology
Ciro Romano, Olga Tortorella, Liliana Dalla Mora, Dario Di Stasio, Ausilia Sellitto, Luigi Elio Adinolfi, Aldo Marrone
Summary: DAAs treatment for chronic hepatitis C can significantly disrupt chronic immune stimulation by eliminating the factors driving autoantibody induction. Although independent persistence of autoantibodies exists in a small fraction of patients who do not achieve clearance following DAAs treatment, long-term vigilance is still required.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Neurosciences
Linh Tran, Jeah Jung, Caroline Carlin, Sunmin Lee, Chen Zhao, Roger Feldman
Summary: The study found that patients with ADRD had a lower risk of initiating DAAs compared to those without ADRD. Behavioral disturbances may reduce the likelihood of DAA use in patients with ADRD. DAA treatment was associated with a significant decrease in mortality among patients with ADRD.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Endocrinology & Metabolism
Chun-Han Cheng, Chia-Ying Chu, Huan-Lin Chen, I-Tsung Lin, Chia-Hsien Wu, Yuan-Kai Lee, Ming-Jong Bair
Summary: This study analyzed the factors associated with insulin resistance (IR) in chronic HCV-infected patients and evaluated the changes in glucose homeostasis after treatment with direct-acting antiviral agents (DAAs). The results showed that obesity, treatment experience, high serum ALT and triglyceride levels, as well as advanced hepatic fibrosis were independently associated with IR in these patients. After viral elimination with DAA therapy, there was a significant reduction in mean HOMA-IR in patients with baseline high IR, HCV genotype 1, and treatment experience.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Virology
Cassia Leal, Jorge Strogoff-de-Matos, Carmem Theodoro, Rosangela Teixeira, Renata Perez, Thais Guarana, Paulo de Tarso Pinto, Tatiana Guimaraes, Solange Artimos
Summary: This study investigated the incidence and risk factors for hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAAs). Among 1075 HCV patients, 4.7% developed HCC within a median follow-up period of 40 months. The main risk factors identified were non-characterized nodules, cirrhosis, high alpha-fetoprotein values, and non-sustained virological response (SVR). The findings suggest that although HCV cure reduces the risk of HCC, vigilance is still required, particularly for cirrhotic patients.
Review
Medicine, General & Internal
Erica Nicola Lynch, Francesco Paolo Russo
Summary: The treatment of hepatitis C (HCV) has been revolutionized by the use of direct-acting antiviral drugs (DAAs), allowing for treatment in advanced stages of liver disease. However, the long-term outcomes and optimal follow-up care for patients after achieving sustained virological response (SVR) are still unclear. Many questions remain regarding patient management after viral eradication, such as predicting liver-related complications and the extent to which viral eradication reduces the risk of liver disease progression. Personalized follow-up care based on individual risk is increasingly supported. This narrative review aims to analyze the impact of viral eradication with DAAs on portal hypertension, hepatocellular carcinoma, and extrahepatic manifestations, as well as summarize indications for optimal follow-up care of HCV patients treated with DAAs.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Eric Kauffman-Ortega, Jesus Ruiz-Manriquez, Antonio Olivas-Martinez, Alejandro Campos-Murguia, Nayelli C. Flores-Garcia, Ernesto Marquez-Guillen, Silvia Lopez-Yanez, Francisco Sanchez-avila, Liz Toapanta-Yanchapaxi, Victor M. Paez-Zayas, Ignacio Garcia-Juarez
Summary: In a Mexican cohort, DAA therapy in LT patients with recurrence of HCV infection showed high efficacy and an acceptable safety profile.
ARCHIVES OF MEDICAL RESEARCH
(2021)
Article
Health Care Sciences & Services
Zehra Karacaer, Banu Cakir, Hakan Erdem, Kenan Ugurlu, Gul Durmus, Nevin Koc Ince, Cinar Ozturk, Rodrigo Hasbun, Ayse Batirel, Esmeray Mutlu Yilmaz, Ilkay Bozkurt, Mustafa Sunbul, Aynur Aynioglu, Aynur Atilla, Ayse Erbay, Ayse Inci, Cigdem Kader, Elif Tukenmez Tigen, Gokhan Karaahmetoglu, Seher Ayten Coskuner, Ebru Dik, Huseyin Tarakci, Selma Tosun, Fatime Korkmaz, Servet Kolgelier, Fatma Yilmaz Karadag, Serpil Erol, Kamuran Turker, Ceyda Necan, Ahmet Melih Sahin, Pinar Ergen, Gulsen Iskender, Pinar Korkmaz, Esma Gulesen Eroglu, Yasemin Durdu, Mehmet Ulug, Suna Secil Deniz, Filiz Koc, Saygin Nayman Alpat, Nefise Oztoprak, Omer Evirgen, Hamdi Sozen, Mustafa Dogan, Selcuk Kaya, Safak Kaya, Mustafa Altindis, Emel Aslan, Recep Tekin, Busra Ergut Sezer, Kevser Ozdemir, Gulden Ersoz, Ahmet Sahin, Ilhami Celik, Emsal Aydin, Aliye Bastug, Rezan Harman, Hacer Deniz Ozkaya, Emine Parlak, Ilknur Yavuz, Suzan Sacar, Senol Comoglu, Ercan Yenilmez, Fatma Sirmatel, Ilker Inanc Balkan, Yesim Alpay, Mustafa Hatipoglu, Affan Denk, Gunes Senol, Mehmet Bitirgen, Mehmet Faruk Geyik, Rahmet Guner, Ayten Kadanali, Ahmet Karakas, Mustafa Namiduru, Hatice Udurgucu, Rukiye Pinar Boluktas, Ergenekon Karagoz, Necati Ormeci
HEALTH AND QUALITY OF LIFE OUTCOMES
(2016)
Article
Medicine, General & Internal
Ercan Yenilmez, Deniz Kakalicoglu, Fatma Bozkurt, Mine Filiz, Aysegul Akkol Camurcu, Elif Ozge Damar Midik, Hande Berk Cam, Eren Arkali, Seval Bilgic Atli, Ahmet Sahin, Sibel Yorulmaz Goktas, Halil Erkan, Mehmet Resat Ceylan, Merve Kacar Eker, Hava Kaya, Zehra Karacaer, Ersin Tural, Ilyas Dokmetas, Levent Gorenek, Sukran Kose
Summary: The study in Turkey revealed that the most common causes of FUO were infections, malignancies, autoimmune/inflammatory diseases, miscellaneous diseases, and undiagnosed cases. The etiological spectrum did not differ significantly in elderly people, but infections were more frequent in Eastern Turkey.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
(2021)
Article
Microbiology
Ayse Ozlem Mete, Enes Erbagci, Ahmet Sahin, Kubra Kocak, Elif Gucyetmez, Sezgin Barutcu, Ilkay Karaoglan
Summary: This study investigated the etiological factors, clinical findings, and diagnostic methods in patients with fascioliasis. The study identified a high incidence of the disease among patients, with main symptoms including abdominal pain, fever, nausea and vomiting, and weakness and fatigue. Measurement of eosinophil levels can assist in the diagnosis of fascioliasis.
FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI
(2023)
Article
Microbiology
Ahmet Sahin, Ozlem Akay, Mehmet Celik, Ayse Ozlem Mete
Summary: In this study, it was found that FIB-4 and King's scores can more safely distinguish between low and high fibrosis.
FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI
(2023)
Article
Medicine, General & Internal
Ahmet Sahin, Sinem Bayrakci, Selda Aslan
Summary: This study investigated the ratios of lactate/albumin, procalcitonin/albumin, and blood urea nitrogen/albumin for predicting 14- and 28-day mortality in uroseptic patients. The results suggest that the lactate/albumin and blood urea nitrogen/albumin ratios can serve as early prognostic markers until more reliable markers are identified.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
(2023)
Article
Medicine, General & Internal
Sezgin Barutcu, Abdullah Emre Yildirim, Ahmet Sahin, Murat Taner Gulsen
Summary: This study evaluated inflammatory markers and found that the combination of LMR and CRP can be used as a novel, low-cost, and non-invasive test to predict treatment response.
MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL
(2022)
Article
Medicine, General & Internal
Ahmet Sahin, Halim Bayram, Mustafa Namiduru, Ilkay Karaoglan, Rezan Harman, Gonul Bakir, Abdulkadir Daldal, Yasemin Balkan
Article
Medicine, General & Internal
Ahmet Sahin, Mustafa Namiduru, Ilkay Karaoglan
Article
Infectious Diseases
Ahmet Sahin, Sema Tekin Sahin, Mustafa Namiduru, Ilkay Karaoglan, Vuslat Bosnak
MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS
(2016)
Article
Medicine, General & Internal
Ahmet Sahin, Vuslat Kecik-Bosnak, Sema Tekin-Sahin, Mustafa Namiduru, Ilkay Karaoglan
Article
Medicine, General & Internal
Vuslat Kecik Bosnak, Ilkay Karaoglan, Mustafa Namiduru, Ahmet Sahin
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
(2013)